|1.||Jain, Rakesh K: 17 articles (10/2015 - 01/2007)|
|2.||Jürgensmeier, Juliane M: 17 articles (07/2014 - 05/2005)|
|3.||Batchelor, Tracy T: 16 articles (10/2015 - 01/2007)|
|4.||Sorensen, A Gregory: 11 articles (01/2014 - 01/2007)|
|5.||Wen, Patrick Y: 10 articles (10/2015 - 01/2007)|
|6.||Duda, Dan G: 8 articles (10/2015 - 01/2007)|
|7.||Ivy, S Percy: 8 articles (01/2015 - 08/2010)|
|8.||Wedge, Stephen R: 7 articles (05/2011 - 05/2005)|
|9.||Ancukiewicz, Marek: 6 articles (11/2013 - 01/2007)|
|10.||Ivy, Percy: 6 articles (09/2013 - 01/2007)|
12/01/2009 - "Cediranib treatment (8 and 12 days) led to a significant reduction in tumor size (42-50%) and a highly significant reduction in MVD (30-55%) versus controls. "
08/01/2007 - "This effect preceded a significant reduction in tumor microvessel density, which was detectable following 52 h of AZD2171 treatment. "
02/01/2013 - "No change between the pre- and post-treatment tumor apparent diffusion coefficients in either the cediranib- or vehicle-treated group was observed over the course of this study. "
12/01/2011 - "This phase I, single-center, dose-finding study was designed primarily to investigate the safety and pharmacokinetics (PK) of cediranib with various anticancer regimens in patients with advanced solid tumors. "
01/01/2011 - "This contrasts with a clinical study that observed a significant decrease in tumor rVCI, ADC and volume with cediranib therapy. "
|2.||Glioblastoma (Glioblastoma Multiforme)
06/10/2010 - "We performed a phase II study of cediranib in patients with recurrent glioblastoma. "
01/01/2014 - "Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation."
04/01/2013 - "In a panel of 10 glioblastoma cell lines, we showed that cediranib was the most potent. "
10/01/2011 - "T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients."
06/01/2011 - "Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma."
01/01/2015 - "Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma."
05/01/2012 - "These findings are clinically relevant to the efficacy of cediranib chemotherapy in glioma."
08/01/2015 - "This improved effect, compared to other therapeutic approaches involving AZD2171, was shown to affect both tumor vasculature and the glioma cells. "
07/01/2013 - "In the U87 intracerebral glioma model, within the first day of administration of cediranib, the intratumoral concentrations of TMZ in tumor ECF were slightly, but not statistically significantly, increased when compared to the treatment of TMZ alone with radiographic evidence of a normalized BBB."
05/01/2012 - "Because of its potent antiangiogenic and antitumor activities, cediranib has been evaluated for therapy in glioma, a primary brain tumor. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
10/10/2012 - "Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II)."
08/01/2012 - "Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer."
04/01/2012 - "Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study."
02/15/2009 - "Purposes of this study were to determine the recommended phase II dose of cediranib in combination with standard doses of modified FOLFOX-6 (mFOLFOX-6), and the tolerability, safety, pharmacokinetics, and antitumor activity of this combination in patients with untreated metastatic colorectal cancer. "
07/01/2013 - "KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib."
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/01/2009 - "This study evaluated escalating cediranib doses with combination chemotherapy in advanced non-small cell lung cancer patients. "
04/10/2008 - "This study evaluated escalating doses of AZD2171 in combination with standard chemotherapy in patients with advanced non-small-cell lung cancer. "
11/01/2015 - "Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture."
01/01/2010 - "PURPOSE This phase II/III double-blind study assessed efficacy and safety of cediranib with standard chemotherapy as initial therapy for advanced non-small-cell lung cancer (NSCLC). "
06/01/2008 - "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies."
|1.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||4- ((4- Fluoro- 2- methyl- 1H- indol- 5- yl)oxy)- 6- methoxy- 7- (3- (pyrrolidin- 1- yl)propoxy)quinazoline (AZD2171)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)